New Blood Pool Contrast Agent - Ablavar

......................................................................................................

There have been quite a number of discussions recently on "Ablavar" - the newly FDA-approved blood pool contrast agent for use in magnetic resonance angiography (MRA) to evaluate aortoilac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease (PVD). Is anyone out there who has experience in the clinical use of Ablavar willing to share with us the safety and efficacy of this blood pool contrast agent? MRA images using Ablavar, if available, will be awesome and most welcome. The images can be sent to me through email and I'll post them up here for sharing.

Illustrated below is one of the clinical examples of the applicaton of blood pool contrast agent from www.bloodpoolagents.com:

(Click on image to enlarge)

More information on Blood Pool Agents.

Tags: Ablavar, Gadofosveset trisodium, Gd, MRA, AIOD, PVD, blood pool contrast agent, aneurysm spurium, thrombosis

Reference:
Goyen M et al. MR angiography of aortoiliac occlusive disease: a phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325.Radiology. 2005;236(3):825-833.

Rapp JH et al. Aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease: safety and efficacy of gadofosveset-enhanced MR angiography—multicenter comparative phase III study. Radiology. 2005;236(1):71-78.

Perreault P et al. MR angiography with gadofosveset trisodium for peripheral vascular disease: phase II trial.Radiology. 2003;229(3):811-820.

T1 Values in Infarcted & Noninfarcted Myocardium for Magnevist & MultiHance

Tags: Relaxation time, T1, Inversion time, TI, null point, Gadopentetate, Gadobenate, Magnevist, MultiHance, infarcted myocardium, noninfarcted myocardium

Source:

Schlosser et al. Myocardial infarct: depiction with contrast-enhanced MR imaging--comparison of gadopentetate and gadobenate. Radiology (2005) vol. 236 (3) pp. 1041-6.

Null Point for Late Gd Enhancement

Tags: Inversion Time, TI, Gadolinium, Late Gadolinium Enhancement, LGE

Source:

Yamrozik JA, Meister J, Geetha R, et al. Combined effects of Gadolinum dosage and delay on myocardial nulling. Journal of Cardiovascular Magnetic Resonance (2007) 9, 477–491.

Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy (ARVD/C)

Tags: ARVD, ARVC, fatty infiltration, myocardial fibrosis, traiangle of dysplasia, protocol, RV 2-chamber view

Sources:

Standardized CMR protocols from SCMR

Jain et al. Role of cardiovascular magnetic resonance imaging in arrhythmogenic right ventricular dysplasia. Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance (2008) vol. 10 (1) pp. 32

Covidien contraindicates use of its Optimark gadoversetamide injection

• Click here to learn more...

Keywords: GBMCA, NSF, Nephrogenic Systemic Fibrosis

GBMCA & NSF

Other relevant document(s) for reference:

• Manual on Contrast Media, version 6, 2008, ACR
• European Medicines Agency (EMEA) makes recommendations to minimize risk of NSF with GBMCA
• Q&A on the review of GBMCA by EMEA